Palo Alto Investors’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Palo Alto Investors’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-31,330	Closed	-$208K	–	31
2022 Q3	$208K	Hold	31,330	–	–	0.02%	31
2022 Q2	$152K	Hold	31,330	–	–	0.01%	33
2022 Q1	$293K	Hold	31,330	–	–	0.02%	34
2021 Q4	$372K	Hold	31,330	–	–	0.02%	36
2021 Q3	$357K	Hold	31,330	–	–	0.02%	39
2021 Q2	$562K	Hold	31,330	–	–	0.03%	37
2021 Q1	$485K	Hold	31,330	–	–	0.03%	38
2020 Q4	$382K	Hold	31,330	–	–	0.02%	38
2020 Q3	$403K	Hold	31,330	–	–	0.02%	40
2020 Q2	$318K	Hold	31,330	–	–	0.02%	37
2020 Q1	$254K	Hold	31,330	–	–	0.02%	34
2019 Q4	$271K	Hold	31,330	–	–	0.01%	33
2019 Q3	$193K	Hold	31,330	–	–	0.01%	35
2019 Q2	$520K	Buy	31,330 +2,775	+10%	+$48.2K	0.03%	33
2019 Q1	$477K	Buy	+28,555	New	+$411K	0.02%	33
2016 Q4	–	Sell	-15,879	Closed	-$116K	–	40
2016 Q3	$116K	Hold	15,879	–	–	0.01%	42
2016 Q2	$81K	Buy	15,879 +1,125	+8%	+$20.7K	0.01%	45
2016 Q1	$318K	Hold	14,754	–	–	0.02%	42
2015 Q4	$451K	Hold	14,754	–	–	0.03%	41
2015 Q3	$492K	Buy	+14,754	New	+$833K	0.02%	44

Other funds holding MRNS

LPC

Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Antara Capital New York $30.2K AUM 5.24% 1-Year Est. Return

Palo Alto Investors's MRNS Position: Q4 2022 in Review

Palo Alto Investors sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q4 2022, closing a stake of 31,330 shares — an estimated $208K sold.

Palo Alto Investors first reported a position in MRNS in Q3 2015 and held it in 20 quarters. The position peaked at $562K in Q2 2021. 74 funds tracked by Wall St. Rank hold MRNS as of Q4 2022.

Palo Alto Investors reported no remaining Marinus Pharmaceuticals, Inc position as of Q4 2022 after selling out during the quarter.
Palo Alto Investors sold 31,330 Marinus Pharmaceuticals, Inc shares in Q4 2022, an estimated $208K.
Palo Alto Investors first reported a position in Marinus Pharmaceuticals, Inc in Q3 2015 and held it in 20 quarters.
Palo Alto Investors's Marinus Pharmaceuticals, Inc position peaked at $562K in Q2 2021.
74 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2022.

Based on Palo Alto Investors's 13F filing for Q4 2022, filed 14 Feb 2023.